bioRxivBiochemistryPreprint
De novo design of phosphotyrosine peptide binders
Magnus S. BaueriD, Jason Z. ZhangiD, Kejia WuiD, Gyu Rie LeeiD, Brian CoventryiD, Isabella M SilvestriiD, Kody A. KluptiD, Jiuhan Shi, Rafael I. BrentiD, Xinting LiiD, Carolina MölleriD, Nicole RoullieriD, Dionne K. VafeadosiD, Indrek KalvetiD, Rebecca SkotheimiD, Siyu ZhuiD, Amir MotmaeniD, Luca C HerrmanniD, Pascal Sturmfels, Doug TischeriD, Han Altae-TraniD, David JuergensiD, Rohith KrishnaiD, Woody AherniD, Jason YimiD, , David A. BakeriD
Abstract
Phosphorylation on tyrosine is a key step in many signaling pathways. Despite recent progress in de novo design of protein binders, there are no current methods for designing binders that recognize phosphorylated proteins and peptides; this is a challenging problem as phosphate groups are highly charged, and phosphorylation often occurs within unstructured regions. Here we introduce RoseTTAFold Diffusion 2 for Molecular Interfaces (RFD2-MI), a deep generative framework for the design of binders for protein, ligand, and covalently modified protein targets. We demonstrate the power and versatility of this method by designing binders for four critical phosphotyrosine sites on three clinically relevant targets: Cluster of Differentiation 3 (CD3{varepsilon}), Epidermal Growth Factor Receptor (EGFR), Insulin Receptor (INSR) and Signal Transducer and Activator of Transcription 5 (STAT5). Experimental characterization shows that the designs bind their phosphotyrosine containing targets with affinities comparable to native binding sites and have negligible binding to non-phosphorylated targets or phosphopeptides with different sequences. X-ray crystal structures of generated binders to CD3{varepsilon} and EGFR are very close to the design models, demonstrating the accuracy of the design approach. A designed binder to an EGFR intracellular region phosphorylated upon EGF activation co-localizes with the receptor following EGF stimulation in single-particle tracking (SPT) experiments, demonstrating pY specific recognition in living cells. RFD2-MI provides a generalizable all-atom diffusion framework for probing and modulating phosphorylation-dependent signaling, and more generally, for developing research tools and targeted therapeutics against post-translationally modified proteins.
- assay: protein structure
- research focus: drug response / drug discovery
- approach: deep learning
- approach: diffusion model
- Citations
- 4
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Improved protein binder design using -pairing targeted RFdiffusion
Isaac Sappington, Martin Toul, … David A. Baker·Nature CommunicationsPeer-reviewed·Jan 10, 2026
- De novo design of high-affinity protein binders to bioactive helical peptides
S. Vazquez Torres, P. J. Y. Leung, … D. Baker·bioRxiv·Dec 10, 2022
- De novo protein design enables targeting of intractable oncogenic interfaces
Varshika Ram Prakash, Yusuf Najy, … Benjamin L. Kidder·bioRxiv·Oct 22, 2025
- Revisiting the phosphotyrosine binding pocket of Fyn SH2 domain led to the Identification of novel SH2 superbinders
- Seed-Guided De Novo Design Expands the Structural Diversity of Antitoxin Protein Binders
Dustin Britton, Dia A. Ghose, … Amy E. Keating·bioRxiv·Aug 4, 2026
- Rational design of a protein-protein interaction inhibitor that activates Protein Tyrosine Phosphatase 1B.
Avinash D. Londhe, Sophie Rizzo, … Benoît Boivin·bioRxiv·Mar 21, 2026